tradingkey.logo
tradingkey.logo
Search

Simulations Plus Inc

SLP
Add to Watchlist
18.500USD
0.0000.00%
Close 10-05 16:00(ET)
374.07MMarket Cap
LossP/E TTM

About Simulations Plus Inc Company

Simulations Plus, Inc. is a provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. It operates through two segments: software and services. The Company’s business units include cheminformatics, physiologically based pharmacokinetics, clinical pharmacology and pharmacometrics, quantitative systems pharmacology, adaptive learning & insights and medical communications. The Company operates in biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry. It delivers simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Its cutting-edge technology is licensed and utilized by pharmaceutical, biotechnology, and regulatory agencies worldwide.

Simulations Plus Inc Profile

Ticker SymbolSLP
Company nameSimulations Plus Inc
IPO dateJun 18, 1997
CEOO'Connor (Shawn M)
Number of employees212
Security typeOrdinary Share
Fiscal year-endJun 18
Address800 Park Offices Drive, Suite 401
CityRESEARCH TRIANGLE PARK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code27709
Phone16617237723
Websitehttps://www.simulations-plus.com/
Ticker SymbolSLP
IPO dateJun 18, 1997
CEOO'Connor (Shawn M)

Company Executives of Simulations Plus Inc

Name
Name/Position
Position
Shareholding
Change
Dr. Hon. Walter S. Woltosz
Dr. Hon. Walter S. Woltosz
Independent Director
Independent Director
5.00K
-64042.62%
Mr. Steven Chang
Mr. Steven Chang
Global Head - Strategic Alliances
Global Head - Strategic Alliances
--
--
Paul Labute
Paul Labute
President
President
--
--
Charles Mullens
Charles Mullens
Director
Director
--
--
Matteo Foderaro
Matteo Foderaro
Director
Director
--
--
Dr. Viera Lukacova
Dr. Viera Lukacova
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Erik Guffrey
Mr. Erik Guffrey
Co-Chief Product and Technology Officer
Co-Chief Product and Technology Officer
--
--
Mr. Josh Fohey
Mr. Josh Fohey
Chief Operating Officer
Chief Operating Officer
--
--
Ms. Lisa Fortuna
Ms. Lisa Fortuna
Investor Relations
Investor Relations
--
--
Mr. Murry Alper
Mr. Murry Alper
Global Head - Medical Communications
Global Head - Medical Communications
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Hon. Walter S. Woltosz
Dr. Hon. Walter S. Woltosz
Independent Director
Independent Director
5.00K
-64042.62%
Mr. Steven Chang
Mr. Steven Chang
Global Head - Strategic Alliances
Global Head - Strategic Alliances
--
--
Paul Labute
Paul Labute
President
President
--
--
Charles Mullens
Charles Mullens
Director
Director
--
--
Matteo Foderaro
Matteo Foderaro
Director
Director
--
--
Dr. Viera Lukacova
Dr. Viera Lukacova
Chief Scientific Officer
Chief Scientific Officer
--
--

FAQs

Who are the top five shareholders of Simulations Plus Inc?

The top five shareholders of Simulations Plus Inc are: Dr. Hon. Walter S. Woltosz

How many institutions hold shares of Simulations Plus Inc (SLP)?

As of 2026Q1, 432 institutions hold shares of Simulations Plus Inc, with a combined market value of approximately 17.68M, accounting for 87.48% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -4627215.00.

What is the biggest source of revenue for Simulations Plus Inc?

In 2026Q1, the Software licenses business generated the highest revenue for Simulations Plus Inc, amounting to 12.61M and accounting for 57.61% of total revenue.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.